Robert J. Penny, M.D., Ph.D.,
CEO - Caris MPI
Director, Chief Medical Officer, Chief Operating Officer - International Genomics Consortium
Executive Director, expO (The Expression Project for Oncology)

Dr. Penny is the founder and Chief Executive Officer of Caris MPI, the first company to commercially introduce gene expression into oncology in the U.S. He is one of the co-founders of the International Genomics Consortium (IGC), the Chief Medical and Operating Officer of IGC, and the Executive Director of their national expression project for oncology (expO). Dr. Penny is the Principle Investigator for The Cancer Genome Atlas Project and Chairs the NIH Biospecimen, Biomolecule and Production Working Group. Dr. Penny is a recognized expert in the translation of diagnostics into patient care as well as in biorepositories. He has established two national esoteric reference medical laboratories, a national tissue bank and analysis center, and a national genomics program. He has helped bring cellular and molecular diagnostic, prognostic and therapeutic testing to patients throughout the nation with leukemia, lymphoma and solid tumors. He has headed up genomic strategies for AmeriPath, the largest provider of anatomic pathology in the United States.

Dr. Penny received his B.S., M.S., Ph.D. (Genetics) and M.D. from the University of Arizona and then went on to receive his pathology training at Harvard's Brigham & Women's Hospital in Boston, Massachusetts, where he served as chief resident and completed fellowships in hematopathology and surgical pathology. Dr. Penny's contributions include a textbook in oncology, publication of articles, and directorship roles in laboratory management.

Daniel Von Hoff, M.D., F.A.C.P.,
Executive Director, Tissue Banking and Analysis Center Inc.

Dr. Von Hoff is Executive Vice President of TGen, and is an internationally recognized leader in cancer drug development. He brings unparalleled clinical expertise to Caris MPI. Dr. Von Hoff also serves as Professor of Medicine, Molecular and Cellular Biology and Pathology at the University of Arizona. Dr. Von Hoff served as the Director of the Arizona Cancer Center at the University of Arizona from 2003 to April of 2005. He is also Chief Scientific Officer for U.S. Oncology.

Dr. Von Hoff's major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, CPT-11, and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies.

Dr. Von Hoff's laboratory interests and contributions have been in the area of in vitro drug sensitivity testing to individualize treatment for the patient, mechanisms of gene amplification, particularly of extrachromosomal DNA, and understanding of and targeting telomere maintenance mechanisms. He and his laboratory are now concentrating on discovery of new targets in pancreatic cancer. He has published more than 493 papers, 122 book chapters, and more than 832 abstracts.

Dr. Von Hoff is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder and board member of ILEX Oncology, Inc. (ILXO, Nasdaq). He is founder and the Editor Emeritus of Investigational New Drugs, The Journal of New Anticancer Agents; Co-Editor of ONE, Oncology Economics; and, Editor of Molecular Cancer Therapeutics. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.

George Poste, D.V.M., Ph.D.

Dr. Poste is the Director of The Biodesign Institute at Arizona State University. In addition to his academic post he serves as Chief Executive of a consulting company, Health Technology Networks, that specializes in the application of genomic technologies and computing in healthcare. He is Chairman of Orchid Biosciences, the leading company in DNA forensic analysis, and serves on the Board of Directors of Monsanto and Exelixis. From 1992 to 1999 he was Chief Science and Technology Officer and President, R&D of SmithKline Beecham (SB). During his tenure at SB he was associated with the successful registration of 31 drug, vaccine and diagnostic products. In 2004 he was named as "R&D Scientist of the Year" by R&D Magazine. He is a Fellow of the Royal Society, and the UK Academy of Medicine, a Distinguished Fellow at the Hoover Institution, Stanford University and a member of the Council for Foreign Relations. He is a member of the Defense Science Board of the US Department of Defense. He also serves as a member of the National Academy Sciences Working Group on Biological Weapons, the Forum on Microbial Threats of the Institute of Medicine Board on Global Health and the Institute of Medicine Committee on Advances in Technology and New Generation Biowarfare Threats.

Michael Bittner, Ph.D.

Dr. Bittner, the Senior Investigator and Director of TGen's Molecular Diagnostics and Target Validation Division, provides crucial scientific leadership and gene expression expertise. Dr. Bittner worked at Monsanto Corp. and Amoco Corp. developing products based on practical applications of biotechnology before spending ten years at the Cancer Genetics Branch of the National Human Genome Research Institute developing measurement and analysis methods for high-throughput functional genomic analysis.

David Mallery, Esq., M.B.A.,
President

David Mallery is a co-founder and oversees the financial, legal and corporate development. He was the founding (pro-bono) Chief Financial Officer of IGC. He is also the Managing Director of a private placement firm in San Diego, CA, and Phoenix, AZ. Mr. Mallery was formerly the Principal Venture Analyst for the Calvert Group's venture and equity fund investments, helping place investments in life sciences, biotechnology, and resource conservation. From 1993 to 1996, he helped establish an independent biological science agency at the U.S. Department of the Interior in Washington, DC. Mr. Mallery is a life member of the Council on Foreign Relations in New York.

David Mallery received a B.A. in Human Biology and Studio Art from Stanford University and a Juris Doctor and a Masters of Business Administration from the University of Colorado at Boulder. He is a member of the Colorado Bar Association and the District of Columbia Bar Association.